Logo image of RNTX

REIN THERAPEUTICS INC (RNTX) Stock Fundamental Analysis

USA - NASDAQ:RNTX - US00887A2042 - Common Stock

1.6 USD
+0.04 (+2.56%)
Last: 11/7/2025, 8:15:14 PM
1.58 USD
-0.02 (-1.25%)
After Hours: 11/7/2025, 8:15:14 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RNTX. RNTX was compared to 534 industry peers in the Biotechnology industry. RNTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RNTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RNTX had negative earnings in the past year.
RNTX had a negative operating cash flow in the past year.
In the past 5 years RNTX always reported negative net income.
RNTX had a negative operating cash flow in each of the past 5 years.
RNTX Yearly Net Income VS EBIT VS OCF VS FCFRNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RNTX has a Return On Assets of -102.91%. This is in the lower half of the industry: RNTX underperforms 76.22% of its industry peers.
RNTX's Return On Equity of -123.20% is in line compared to the rest of the industry. RNTX outperforms 41.20% of its industry peers.
Industry RankSector Rank
ROA -102.91%
ROE -123.2%
ROIC N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
RNTX Yearly ROA, ROE, ROICRNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNTX Yearly Profit, Operating, Gross MarginsRNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

RNTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RNTX has been increased compared to 5 years ago.
RNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNTX Yearly Shares OutstandingRNTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNTX Yearly Total Debt VS Total AssetsRNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.97, we must say that RNTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.97, RNTX is doing worse than 69.29% of the companies in the same industry.
There is no outstanding debt for RNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.97
ROIC/WACCN/A
WACCN/A
RNTX Yearly LT Debt VS Equity VS FCFRNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 0.86 indicates that RNTX may have some problems paying its short term obligations.
RNTX has a worse Current ratio (0.86) than 88.76% of its industry peers.
A Quick Ratio of 0.86 indicates that RNTX may have some problems paying its short term obligations.
The Quick ratio of RNTX (0.86) is worse than 88.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86
RNTX Yearly Current Assets VS Current LiabilitesRNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

RNTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.01%, which is quite good.
EPS 1Y (TTM)17.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNTX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.24% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.96%
EPS Next 2Y33.47%
EPS Next 3Y20.24%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNTX Yearly Revenue VS EstimatesRNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 50M 100M 150M 200M 250M
RNTX Yearly EPS VS EstimatesRNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNTX Price Earnings VS Forward Price EarningsRNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNTX Per share dataRNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

RNTX's earnings are expected to grow with 20.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.47%
EPS Next 3Y20.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REIN THERAPEUTICS INC

NASDAQ:RNTX (11/7/2025, 8:15:14 PM)

After market: 1.58 -0.02 (-1.25%)

1.6

+0.04 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners28.57%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap37.30M
Revenue(TTM)N/A
Net Income(TTM)-59.15M
Analysts80
Price Target10.2 (537.5%)
Short Float %0.11%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.41%
Min EPS beat(2)-24.78%
Max EPS beat(2)-0.04%
EPS beat(4)1
Avg EPS beat(4)-360.27%
Min EPS beat(4)-1451.7%
Max EPS beat(4)35.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)42.86%
PT rev (3m)42.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6%
EPS NY rev (1m)-4.89%
EPS NY rev (3m)-4.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0
BVpS2.06
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.91%
ROE -123.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.04%
ROA(5y)-84.72%
ROE(3y)-92.8%
ROE(5y)-102.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z -7.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y73.96%
EPS Next 2Y33.47%
EPS Next 3Y20.24%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.77%
OCF growth 3YN/A
OCF growth 5YN/A

REIN THERAPEUTICS INC / RNTX FAQ

What is the fundamental rating for RNTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to RNTX.


What is the valuation status for RNTX stock?

ChartMill assigns a valuation rating of 1 / 10 to REIN THERAPEUTICS INC (RNTX). This can be considered as Overvalued.


How profitable is REIN THERAPEUTICS INC (RNTX) stock?

REIN THERAPEUTICS INC (RNTX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for RNTX stock?

The Earnings per Share (EPS) of REIN THERAPEUTICS INC (RNTX) is expected to grow by 73.96% in the next year.